0001140361-22-028093.txt : 20220803
0001140361-22-028093.hdr.sgml : 20220803
20220803200121
ACCESSION NUMBER: 0001140361-22-028093
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220801
FILED AS OF DATE: 20220803
DATE AS OF CHANGE: 20220803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Singer Nicholas Jason
CENTRAL INDEX KEY: 0001828224
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 221134197
MAIL ADDRESS:
STREET 1: 1395 BRICKELL AVENUE
STREET 2: SUITE 800
CITY: MIAMI
STATE: FL
ZIP: 33131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: ALROY INDUSTRIES INC
DATE OF NAME CHANGE: 19850411
4
1
form4.xml
FORM 4
X0306
4
2022-08-01
0000748592
Brooklyn ImmunoTherapeutics, Inc.
BTX
0001828224
Singer Nicholas Jason
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
10355 SCIENCE CENTER DRIVE, SUITE 150
SAN DIEGO
CA
92121
true
Stock Option (right to buy)
0.49
2022-08-01
4
A
0
146100
0
A
2032-08-01
Common Stock, par value $0.005 per share
146100
146100
D
Stock Option (right to buy)
0.49
2022-08-01
4
A
0
165800
0
A
2032-08-01
Common Stock, par value $0.005 per share
165800
165800
D
The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.
The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.
/s/ Nicholas J. Singer
2022-08-03